While the share of ESI enrollees with a GLP-1 drug claim has been increasing, still only a relatively modest number of people have a claim Since 2012, the share of non-elderly adults with ESI that have a GLP-1 drug claim has grown more than eightfold (717.7% increase)
If a mans ED can be corrected by other means (for instance, severe hypogonadism causing ED treatable with testosterone, or an anatomical issue like Peyronies requiring different interventions), those underlying issues should be addressed first
The company said people with insurance may be able to get the drug starting at $25 per month with a Lilly discount card
What the FDA prescribing information says The FDA-approved label for semaglutide injection (Ozempic) states: "Semaglutide causes a delay in gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications." [3] The Wegovy label repeats this language verbatim, and the tirzepatide (Mounjaro) label carries an equivalent warning [4]
In response to shortages, the FDA allowed use of compounded GLP-1 drugs